Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    FOLFOX plus bevacizumab, assessing tumor blood flow
Show Display Options
Rank Status Study
1 Unknown  MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
2 Completed DCE-MRI PET Bevacizumab Study in Rectal Cancer
Condition: Rectal Cancer Patients
Intervention: Drug: Bevacizumab 5 mg/kg

Indicates status has not been verified in more than two years